Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown promising response rates in relapsed and newly diagnosed MM, and bortezomib has recently been reported to inhibit OCLs. We here investigated the effect of lenalidomide on OCL formation and osteoclastogenesis in comparison with bortezomib. Both drugs decreased aVb3-integrin, tartrate-resistant acid phosphatase-positive cells and bone resorption on dentin disks. In addition, both agents decreased receptor activator of nuclear factor-jB ligand (RANKL) secretion of bone marrow stromal cells (BMSCs) derived from MM patients. We identified PU.1 and pERK as major targets of lenalidomide, and nuclear factor of activated T cells of bortezomib, resulting in inhibition of osteoclastogenesis. Furthermore, downregulation of cathepsin K, essential for resorption of the bone collagen matrix, was observed. We demonstrated a significant decrease of growth and survival factors including macrophage inflammatory protein-a, B-cell activating factor and a proliferation-inducing ligand. Importantly, in serum from MM patients treated with lenalidomide, the essential bone-remodeling factor RANKL, as well as the RANKL/OPG ratio, were significantly reduced, whereas osteoprotegerin (OPG) was increased. We conclude that both agents specifically target key factors in osteoclastogenesis, and could directly affect the MM-OCL-BMSCs activation loop in osteolytic bone disease.
Introduction
Multiple myeloma (MM) is a currently incurable malignant plasma cell disorder affecting approximately 15 000 new patients in the United States annually. Novel drugs targeting MM and its microenvironment have shown promising clinical results. 1 Thalidomide and its more potent immunodmodulatory analog (IMiDs) lenalidomide have been successfully used in MM treatment. Specifically, the results of a multicenter, openlabeled, randomized phase 2 study evaluating two dose regimens of lenalidomide for relapsed, refractory myeloma show an overall response rate of lenalidomide alone of 25%. It was well tolerated at 30 mg once daily, with a median overall survival of 28 months and a median progression-free survival of 7.7 months. 2 In two large-phase III studies comparing lenalidomide/dexamethasone versus dexamethasone in relapsed MM, extent and frequency of response, as well as progress free and overall survival, were prolonged in the combined therapy cohort. 3, 4 The proteasome inhibitor bortezomib has potent anti-MM activity with impressive clinical responses, prolonging time to progression and overall survival in patients with relapsed or refractory MM. 5, 6 In spite of these novel agents, osteolytic bone disease remains a major source of morbidity, occurring in 70-80% of MM patients and associated with severe bone pain, pathologic fractures, paralysis through nerve compression, hypercalcemia and death. 7 Bisphosphonates inhibit osteoclast (OCL) activity and have been successfully and widely used for the treatment of MM bone disease; 8 however, complications induced by bisphosphonates can occur including osteonecrosis of the jaw, and their use is not recommended over a long period of time.
Osteolytic lesions are primarily due to a dysregulation of the normal bone-remodeling process, with a decrease of osteoblast (OBL) function accompanied by increased activation of OCLs. In MM, this destructive bone process is enhanced by interaction of MM cells with OCLs in the bone marrow (BM) microenvironment. Specifically, adhesion of MM cells to bone marrow stromal cells (BMSCs) induces secretion of osteolytic factors such as interleukin-6 (IL-6) and receptor activator of NF-kB ligand (RANKL), a tumor necrosis factor (TNF) family cytokine. IL-3 production stimulates osteoclastogenesis directly and enhances the effect of RANKL and of macrophage inflammatory protein-a (MIP-1a), an important growth and survival factor for MM cells and OCL. 9 In addition, MM cells in the BM produce Dickkopf homologue 1, thereby inhibiting OBL activation by blocking Wnt signaling. 10 Clinical observations revealed that bortezomib may trigger OBL activation, evidenced by increased alkaline phosphatase in the serum of MM patients responding to bortezomib treatment. 11 Moreover, treatment with bortezomib in patients with relapsed MM significantly decreased RANKL and C-terminal cross-linking telopeptide of collagen type I (CTX). 12 Recently, von Metzler et al. 13 showed that bortezomib inhibits osteoclastogenesis by downregulation of p38 mitogen-activated protein kinase (MAPK) and AP1. To date, however, the effect of lenalidomide on OCLs remains unknown. Furthermore, it is not clear whether there is an inhibitory effect of lenalidomide or bortezomib on growth and survival factors that trigger osteoclastogenesis and OCL activation. In this study, we investigated whether lenalidomide, similar to bortezomib, affects activation and function of OCLs in the BM microenvironment, osteoclastogenesis and related growths factors, as well as markers of bone turnover in MM.
Materials and methods

Osteoclast formation assay
OCLs were generated in vitro using peripheral blood mononuclear cells (PBMCs) from MM patients. Written informed consent was obtained according to the Declaration of Helsinki. For OCL formation assays, PBMCs were separated by Ficoll-Paque gradient, and nonadherent cells were cultured in 6-or 96-well plates (0.5 Â 0 6 cells per cm 2 ), as previously described.
14 OCLs were generated by culturing cells for 14-21 days in a-minimal essential medium containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (Mediatech Inc., Herndon, VA, USA), as well as 25 ng/ml of macrophage colony-stimulating factor (M-CSF) (R&D Systems, Minneapolis, MN, USA) and RANKL (50 ng/ml) (PeproTech, Rocky Hill, NJ, USA).
Bone marrow stromal cell cultures
BMSCs derived from MM patients were cultured in RPMI and 20% FBS after separation of mononuclear cells via Ficoll-Paque gradient. BMSCs were cultured in 96-well plates (0.5 Â 10 4 cells per cm 2 ). Medium was changed twice weekly. Lenalidomide and bortezomib were diluted in culture medium and added to BMSCs for 72 h. Supernatant was collected and stored at -80 1C.
Osteoclast differentiation and bone resorption assay
After 2 weeks of incubation, OCLs in control and treated groups were fixed with citrate-acetone solution and stained for tartrateresistant acid phosphatase (TRAP) using an acid phosphatase leukocyte staining kit (Sigma Chemical, Saint Louis, MO, USA). TRAP-positive multinucleated OCLs containing three or more nuclei per cell were enumerated using an inverted microscope. Images were obtained using a Leica DM IL microscope (Leica Microsystems, Wetzlar, Germany) and were acquired through IM50 software (Leica Microsystems Imaging Solutions, Cambridge, UK). For bone resorption assays, cells were cultured on dentine slices with RANKL and M-CSF for 3 weeks, in the absence or presence of lenalidomide or bortezomib, and resorbtion lacunae were enumerated using an inverted microscope. PBMCs were cultured (0.5 Â 10 6 cells per well) on dentin slices (Immunodiagnostic Systems Ltd., Boldon, England) in 96-well plates, as per the manufacturer's guidelines. After incubation time, cells were scraped off gently with 0.1% triton. Bone slices were washed in distilled water and stained with 1% toluidine solution. After staining resorption areas with toluidine blue, images were obtained using a Leica DM IL microscope and IM50 software. Bone resorption was measured by enumerating resorption pits.
Flow cytometry
For analysis of cell surface marker expression after 2 weeks of differentiation and incubation in the absence or presence of lenalidomide or bortezomib, OCLs were harvested with cell dissociation buffer (Invitrogen, Carlsbad, CA, USA) and suspended in Dulbecco's phosphate-buffered saline. For OCL detection, cells were stained with aVb3-integrin (fluoresceinconjugated mouse immunoglobulin G 1 (IgG1), CD51/CD61; Chemicon International, Temecula, CA, USA). Following 1-hour incubation at 4 1C with the primary antibody, cells were washed and analyzed using the RXP cytomics software on an Epics flow cytometer (Coulter Immunology, Hialeah, FL, USA).
ELISA
Cytokine secretion in supernatants from OCL cultures was measured using enzyme-linked immunosorbent assay (ELISA). Specifically, OCLs were cultured in 96-well plates for 2 weeks; supernatants were harvested, and MIP-1a, IL-6, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) secretion were measured using DuoSet ELISA development kits (R&D Systems Inc.) and Bender MedSystems (Burlingame, CA, USA), in accordance with manufacturer's instructions. To measure RANKL secretion, BMSCs were cultured in RPMI/ 20% FBS in the presence of lenalidomide or bortezomib. After 72 h, supernatant was harvested and subjected to RANKL ELISA (Bender MedSystems Burlingame).
Western blot analysis
PBMCs were cultured with RANKL (50 ng/ml) and M-CSF (25 ng/ ml) in the presence or absence of lenalidomide or bortezomib. PBMCs were seeded in six-well plates. Cells were harvested at specific time points with cell dissociation buffer (Invitrogen) and lyzed in lysis buffer (50 mM HEPES (N-2-hydroxyethylpiperazine-N 0 2-ethanesulfonic acid), pH 7.4, 150 mM NaCl, 1% NP-40, 30 mM sodium pyrophosphate, 5 mM ethylenediaminetetraacetic acid, 2 mM Na3VO4, 5 mM NaF, 1 mM phenylmethyl sulfonyl fluoride, 5 mg/ml leupeptin and 5 mg/ml aprotinin). Total protein lysates were then subjected to sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and immunoblotted with antibodies against pERK, nuclear factor of activated T cells (NFATe1), c-fos (Santa Cruz Biotechnology, Santa Cruz, CA, USA), as well as PU.1 and cathepsin K (Cell Signaling Technology, Beverly, MA, USA). Antigen-antibody complexes were detected by enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA). The membrane was stripped and reprobed with anti-actin or ERK2 (Cell Signaling Technology) antibody to ensure equal protein loading.
Patient characteristics
Serum from 20 MM patients was obtained before therapy as well as on day 28 of the second cycle and subjected to osteoprotegerin (OPG) and RANKL ELISA (Bender MedSystems Burlingame). Patients enrolled in the study had Durie stage II and III MM, were at least 18-year old, had relapsed or refractory disease after a median of 4 prior chemotherapies, and had given written informed consent in accordance to the Declaration of Helsinki. All patients had radiologically confirmed, extensive osteolytic bone disease (44 osteolytic lesions), and had been treated with bisphosphonates monthly since their disease diagnosis. In total, 55% of the patients had IgG, 25% IgA and 20% Bence Jones proteinuria. Overall response rate was 45% (complete remission, partial remission and minimal response), with 55% stable disease (Supplementary data, Table 1 ).
Statistical analysis
Each experiment was repeated at least three times. All quantitative data are presented as median plus range. Wilcoxon rank-sum test was used for comparisons in all in vitro experiments and of cytokine serum levels at baseline versus after two cycles of lenalidomide monotherapy. All P-values were two-sided, and Po0.05 was considered statistically significant.
Results and discussion
Lenalidomide and bortezomib have been shown to interfere with MM tumor growth and survival in the BM microenvironment and to be effective in the treatment of relapsed and refractory MM. 15, 16 We here report the influence of lenalidomide on osteoclastogenesis in vitro and in vivo, secretion of key factors from BMSCs important for OCL survival as well as OCL formation and activation in MM, and compare these effects with bortezomib.
Inhibition of OCL formation, bone resorption, expression of aVb3-integrin and cathepsin K To rule out severe cytotoxicity in OCL cultures, we first investigated susceptibility of OCL cultures to short-term exposure (72 h) of lenalidomide and bortezomib at different time points and concentrations. Overall, both agents showed only minor cytotoxicity at different time points of OCL development (data not shown).
Next we investigated the effect of lenalidomide and bortezomib on OCL formation and their ability to resorb bone. During osteoclastogenesis, TRAP-negative mononuclear cell progress to pro-OCL and then pre-OCL (small round mononucleated TRAP-positive cells), ultimately fusing to form mature OCL (multinucleated TRAP-positive cells) capable of extensive lacunar resorption. 17 In our study, lenalidomide significantly decreased TRAP-positive and multinucleated cells in a dosedependent manner (lenalidomide at 0 mM: median 70.5%; range 50.0-84.0%; at 2 mM: median 47.0%; range 31.0-77.0%; at 10 mM: median 32.5%; range 14.0-44.0%; Po0.05). As in previous reports, 13 bortezomib inhibited formation of TRAP-positive, multinucleated cells (bortezomib at 0 nM: median 70.5%; range 50.0-84.0%; at 2 nM: median 26.0%; range 11.0-39.0%; Po0.01; at 5 nM: median 17.0%; range 13.0-34.0%; Po0.001) (Figure 1a) . Furthermore, formation of characteristic resorption lacunae was reduced by both lenalidomide (lenalidomide at 0 mM: median 100%; at 2 mM: median 38%; range 15-50%; at 10 mM: median 20%; range 0-35%; Po0.02) and bortezomib (bortezomib at 0 nM: median 100%; at 2 nM: median 3%; range 0-5%; at 5 nM: median 0%; range 0-0% Po0.0001) (Figure 1b) .
Multiple factors are involved in the activation of OCLs that eventually lead to bone resorption. Cathepsin K is the major cysteine protease expressed in OCLs and is important for matrix degradation during bone resorption. It is processed intracellularly, presumably in lysosomal compartments, prior to the release of active enzyme into the resorption lacunae.
18 aVb3-integrin is an important marker of OCL differentiation and a member of a superfamily of adhesion molecules that mediates interactions between cells and the extracellular matrix, activates OCLs and is associated with OCL bone resorption. 19 We here investigated whether lenalidomide altered the expression of aVb3-integrin and cathepsin K in OCLs and found a dosedependent decrease of aVb3-integrin-positive cells (Figure 1c ) (lenalidomide at 0 mM: median 69.3%; range 28.9-89.0%; at 2 mM: median 50.4%; range 21.5-64.2%; at 10 mM: median 39.2%; range 33.6-47.5%); bortezomib decreased these cells more potently (bortezomib at 0 nM: median 69.3%; range 28.9-89.0%; at 2 nM: median 35.0%; range 11.0-79.0%; at 5 nM: median 11.5%; range 5.5-18.8%; Po0.05). Furthermore, western blot analysis showed a dose-dependent downregulation (Figure 1d) . Our results therefore suggest that lenalidomide, similar to bortezomib, interferes with OCL differentiation, cell adhesion, cell fusion and bone resorption during osteoclastogenesis. It is noteworthy that in our bone formation assays, bortezomib seemed to have a stronger inhibitory effect than lenalidomide. Furthermore, compared with MM cell lines, even lower doses of bortezomib could be used, whereas higher ones of lenalidomide were required.
Downregulation of key transcription factors during osteoclastogenesis
The signal transduction pathways modulating osteoclastogenesis have been extensively studied: PU.1 plays a critical role in the early determination phase of osteoclastogenesis, whereas activation of MAPK, and extracellular signal-regulated kinase (ERK), mediates OCL survival and differentiation. 20 PU.1 regulates the differentiation of myeloid cells to OCL precursors; conversely, PU.1-deficient mice develop osteopetrosis. 21 RANKL induces OCL differentiation in the presence of M-CSF. 22 M-CSF triggers activation of phosphatidylinositol-3 (PI-3) kinase/AKT that mediates OCL survival during early and late osteoclastogenesis. M-CSF further stimulates MAPK, ERK and Fos/Jun; RANKL activates TNF receptor-associated factor 6 (TRAF6) and the AP1/c-fos complex. The AP1/c-fos complex is a key regulator of OCL differentiation. Mice lacking c-fos develop osteopetrosis due to defective OCL differentiation, whereas the number of macrophages increases. 23, 24 AP1/c-fos in turn activates Jun N-terminal kinase 1, nuclear factor (NF)-kB and its downstream target NFATc1, a major transcription factor modulating osteoclastogenesis. 25 Pomalidomide (CC-4047, actimid), another IMiD, has been shown to inhibit osteoclastogenesis by downregulating PU.1; 14 Anderson et al. showed that pomalidomide, but not thalidomide, decreased the expression of PU.1. However, no inhibition of c-fos could be found after either pomalidomide or thalidomide treatment. von Metzler et al. 13 reported an inhibitory effect of bortezomib on human osteoclastogenesis, associated with p38 MAPK and AP1 inhibition. They found that bortezomib targeted OCLs especially in the range between 1 and 100 nM, with decreasing effects of bortezomib on more differentiated 26 It acts directly on human OCL progenitors and is involved at later stages of OCL differentiation. 27 Levels of MIP-1a in freshly isolated BM from patients with active MM are higher (range 75-7784 pg/ml) than with stable disease (range 75-190.3 pg/ml), 28 and serum levels of MIP-1a correlated with osteolytic lesion in MM patients. 29 In addition, MIP-1a stimulates proliferation, migration and survival of MM cells. 30 Furthermore, MIP-1a enhances adhesive interactions between MM cells and BMSCs, leading to an increased expression of RANKL and IL-6, thereby increasing bone destruction and tumor burden. Here we examined the effect of lenalidomide and bortezomib on MIP-1a secretion in OCL cultures, and found a dose-dependent decrease in MIP-1a secretion triggered by lenalidomide and bortezomib (lenalidomide at 0 mM: median 171.4 pg/ml; range 159.3-219.6 pg/ml; at 2 mM: median 91.6 pg/ml; range 73.4-100.0 pg/ ml; at 10 mM: median 83.8 pg/ml; range 76.6-86.5 pg/ml; Po0.05) (bortezomib at 0 nM: median 171.4 pg/ml; range 159.3-219.6 pg/ml; at 2 nM: median 115.1 pg/ml; range 72.6-141.2 pg/ml; at 5 nM: median 87.3 pg/ml; range 60.6-103.4 pg/ ml; Po0.05) (Figure 3a) These results indicate that both lenalidomide and bortezomib decrease MIP-1a, one of the most important growth and survival factors of OCLs. BAFF 31 and a proliferation-inducing ligandAPRIL 32 are members of the TNF family (TNF-a) and promote MM cell growth and survival in the BM microenvironment, as well as growth of other B-cell malignancies. 33, 34 Moreaux et al.
35
reported that BAFF and APRIL protect MM cells from apoptosis initiated by IL-6 deprivation and dexamethasone treatment, and also upregulated the anti-apoptotic factor Bcl-2 in MM cells. These protective effects were mediated by activation of NF-kB, PI3K/AKT and MAPK signaling. Importantly, OCL produced Figure 4 Lenalidomide inhibits bone-remodeling markers from patients with relapsed or refractory multiple myeloma (MM). Serum from patients with refractory or relapsed MM was subjected to receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG) enzyme-linked immunosorbent assay (ELISA) before (baseline) and after 2 months of lenalidomide treatment. Lenalidomide treatment significantly decreased RANKL after 2 months (Po0.05). Furthermore, RANKL/OPG ratio was also significantly reduced (Po0.05), whereas OPG secretion was significantly increased (Po0.05).
Lenalidomide, bortezomib inhibit osteoclasts in MM I Breitkreutz et al threefold more BAFF and eightfold more APRIL than BMSCs, thereby promoting MM cell growth and survival. 36 Production of BAFF and APRIL activates both OCLs and MM cells. 37 Importantly, Yaccoby et al. 38 recently reported that BAFF and APRIL were highly upregulated in MM cells co-cultured with OCLs. We here measured levels of BAFF and APRIL secreted in supernatants of RANKL and M-CSF-stimulated OCL cultures and found that both lenalidomide and bortezomib significantly reduced BAFF (lenalidomide at 0 mM: median 127.6 pg/ml; range 32.0-420.0 pg/ml; at 2 mM: median 64.9 pg/ml; range 32.1-288.2 pg/ml; at 10 mM: median 60.1 pg/ml; range 27.6-119.7 pg/ml; Po0.05) (bortezomib at 0 nM: median 127.6 pg/ml; range 32.0-420.0 pg/ml; at 2 nM: median 53.4 pg/ml; range 26.3-214.4 pg/ml; at 5 nM: median 53.3 pg/ml; range 24.9-103.8 pg/ml; Po0.05, respectively) ( Figure 3b ) and APRIL (lenalidomide at 0 mM: median 6.2 ng/ml; range 3.9-7.2 ng/ml; at 2 mM: median 4.9 ng/ml; range 3.6-5.6 ng/ml; at 10 mM: median 4.2 ng/ml; range 3.6-5.2 ng/ml) (bortezomib at 0 nM: median 6.2 ng/ml; range 3.9-7.2 ng/ml; at 2 nM: median 4.1 ng/ ml; range 3.5-5.0 ng/ml; at 5 nM: median 2.1 ng/ml; range 0.6-3.7 ng/ml; Po0.01) (Figure 3c ) secretion. As BAFF and APRIL trigger OCL and MM cell proliferation and survival, these results suggest that both agents decrease important promoters of MM cells and OCLs in the BM microenvironment. It is noteworthy that the inhibitory effect on BAFF, APRIL and MIP1a secretion may in part be caused by cytotoxicity. However, we found only minor cytotoxicity versus significant inhibition of differention into multinucleated and functional OCLs (Figure 1 ). Moreover, cell numbers at time of supernatant harvest were similar in all treatment groups, indicating a minor contribution of cytotoxicity to decrease cytokine levels.
RANKL is the key mediator of osteoclastogenesis and plays a crucial role in bone destruction in malignant bone disease. MM cells also express RANKL, 39 and the level of RANKL expression correlates with the status of osteolytic bone disease in MM. 40 RANKL is produced mainly by BMSCs after adhesion of MM cells; conversely, blockade of RANKL suppressed OCL maturation, bone resorption and tumor development. We here investigated the potential of lenalidomide and bortezomib to interfere with RANKL secretion by BMSCs derived from MM patients. Lenalidomide and bortezomib inhibited RANKL secretion in a dose-dependent manner (lenalidomide at 0 mM: median 13.9 U/l, at 2 mM: 8.5 U/l, at 10 mM: 7.6 U/l; bortezomib at 0 nM: median 15.0 U/l, at 5 nM: 9.1 U/l, at 5 nM: 2.9 U/l) (Figure 3d) , thereby contributing to the inhibition of osteoclastogenesis.
Lenalidomide significantly inhibits bone-remodeling markers in patient's serum Lenalidomide, bortezomib inhibit osteoclasts in MM I Breitkreutz et al and stimulating OBLs. In MM, the ratio of RANKL/OPG is increased due to both enhanced RANKL production and decreased OPG production triggered by adhesion of MM cells to BMSCs. 42 Serum levels of soluble RANKL/OPG in MM patients correlate with the extent of bone disease and survival. 43 Terpos et al. 44 investigated the influence of thalidomide and dexamethasone on bone disease in 35 patients with relapsed or refractory MM, and found a normalization of bone-remodeling markers. Specifically, they measured RANKL, OPG and markers of bone resorption and function, and found that prior to Thal/ Dex treatment, MM patients had an increased RANKL/OPG ratio, whereas treatment with Thal/Dex resulted in normalization of this ratio. We here investigated the effect of lenalidomide on osteolytic bone disease from patients with relapsed or refractory MM treated in a randomized trial comparing 30 mg daily versus 15 mg twice daily lenalidomide. The median OPG at baseline was significantly lower (median 8.8 pg/ml, range 7.7-12.6 pg/ml) than after treatment (median 10.4 pg/ml, range 8.5-15 pg/ml) (Po0.05) (Figure 4 ). Lenalidomide also significantly inhibited the secretion of RANKL in patient's serum (baseline: median 17 pg/ml, range 9.0-36 pg/ml; 2 months after therapy: median 4.2 pg/ml, range 2.5-36 pg/ml) (Po0.05). Finally, the ratio of RANKL/OPG was significantly higher before than after therapy (baseline: median 2.2 pg/ml, range 1.1-3.0 pg/ml; 2 months after therapy: median 0.5 pg/ml, range 0.3-2.6 pg/ml) (Po0.05) (Figure 4) . Therefore, lenalidomide specifically reduces serum markers of osteolytic bone disease in MM patients. It is noteworthy that all patients received bisphosphonates from time of disease diagnosis, including after relapse, so our results are mainly due to relapse therapy with lenalidomide, rather than bisphosphonate treatment.
In conclusion, it has not been clear whether new drugs in MM directly target mediators of bone disease or whether these effects are due to a decrease in MM tumor burden. Importantly, we demonstrated that lenalidomide inhibits OCL formation and activation through inhibition of key factors during osteoclastogenesis, including PU.1, and pERK. We further showed that lenalidomide and bortezomib block OCL-derived secretion of growth and survival factors (MIP-1a, BAFF, APRIL) and RANKL secretion from BMSCs, indicating that both agents not only reduce MM burden, but also prevent osteoclastogenesis directly.
Of clinical relevance, we demonstrated that lenalidomide treatment decreased serum bone-remodeling markers in patients with refractory and relapsed MM. Potent anti-MM agents in combination with bisphosphonates reduce OCL activity through reduction of tumor burden, and future trials will determine whether bortezomib and lenalidomide, used either alone or combined with bisphosphonates, can further reduce OCL activity and more effectively prevent osteolytic lesions in MM.
